Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07041203 · ClinicalTrials.gov registry record · Phase 1
Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
A Phase 1 study, sponsored by Kristina Simonyan.
- Not yet
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07041203 is a Phase 1 study that has not yet begun recruiting, run by Kristina Simonyan. The registered enrollment target is 8 participants.
The verdict
NCT07041203, a Phase 1 study, has not yet begun recruiting, sponsored by Kristina Simonyan.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
Interventions
- DRUG sodium oxybate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07041203
The ClinicalTrials.gov registry entry for NCT07041203 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kristina Simonyan, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium oxybate is the first listed.
NCT07041203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07041203 about?
NCT07041203 is a clinical study titled "Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor". Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.
What is the current status of trial NCT07041203?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-10-01. Estimated completion is 2027-09-30.
What interventions are being tested in trial NCT07041203?
The interventions under investigation include: sodium oxybate (DRUG).
Who is sponsoring clinical trial NCT07041203?
This trial is sponsored by Kristina Simonyan, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.